Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Debt (2016 - 2017)

Historic Total Debt for Corcept Therapeutics (CORT) over the last 2 years, with Q2 2017 value amounting to $4.6 million.

  • Corcept Therapeutics' Total Debt fell 7949.42% to $4.6 million in Q2 2017 from the same period last year, while for Jun 2017 it was $4.6 million, marking a year-over-year decrease of 7949.42%. This contributed to the annual value of $14.7 million for FY2016, which is N/A changed from last year.
  • Corcept Therapeutics' Total Debt amounted to $4.6 million in Q2 2017, which was down 7949.42% from $10.1 million recorded in Q1 2017.
  • Corcept Therapeutics' Total Debt's 5-year high stood at $25.0 million during Q1 2016, with a 5-year trough of $4.6 million in Q2 2017.